References
- The Korean Society of Osteoporosis. Osteoporosis and Osteoporotic Fracture Fact Sheet 2019. Available from https://www.ksbmr.org/bbs/index.html?code=fact&category=&gubun=&page=1&number=703&mode=view&keyfield=&key=. Accessed Feburary 19, 2022.
- Choi SH, Kim DY, Koo JW, Lee SG, Jeong SY, Kang CN. Incidence and Management Trends of Osteoporotic Vertebral Compression Fractures in South Korea: A Nationwide Population-Based Study. Asian Spine J 2020;14(2):220-8. https://doi.org/10.31616/asj.2019.0051
- Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361(8):756-65. https://doi.org/10.1056/NEJMoa0809493
- Cummings SR, Ferrari S, Eastell R, et al. Vertebral fractures after discontinuation of denosumab: A post hoc analysis of the randomized placebo-controlled FREEDOM trial and Its extension. J Bone Miner Res 2018;33(2):190-8. https://doi.org/10.1002/jbmr.3337
- Daga N, Joseph F. Denosumab-induced severe hypocalcaemia in a patient with vitamin D deficiency. BMJ Case Rep 2020;13(8):e234508. https://doi.org/10.1136/bcr-2020-234508
- Nakamura Y, Suzuki T, Kamimura M, et al. Vitamin D and calcium are required at the time of denosumab administration during osteoporosis treatment. Bone Res 2017;5:17021. https://doi.org/10.1038/boneres.2017.21
- Carroll R, Matfin G. Endocrine and metabolic emergencies: hypocalcaemia. Ther Adv Endocrinol Metab 2010;1(1):29-33. https://doi.org/10.1177/2042018810366494
- Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020 Update. Endocr Pract 2020; 26(Suppl 1):1-46.
- Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004;19(7):1059-66. https://doi.org/10.1359/JBMR.040305
- AMGEN. Approved package insert of Prolia® Pre-filled Syringe. Available from http://www.amgen.co.kr/products/prolia. Accessed Feburary 19, 2022.
- Endocrine Today. Denosumab increasingly prescribed in osteoporosis treatment. Available from https://www.healio.com/news/endocrinology/20210329/denosumab-increasinglyprescribed-in-osteoporosis-treatment. Accessed April 17, 2022.
- Fleish H. Bisphosphonates in bone disease. From the Laboratory to Patient, 4th ed. San Diego: Academic Press 2000: 30-3.
- Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 2017;5(7):513-23. https://doi.org/10.1016/S2213-8587(17)30138-9
- Bone HG, Bolognese MA, Yuen CK, et al. Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass. J Clin Endocrinol Metab 2011;96(4):972-80. https://doi.org/10.1210/jc.2010-1502
- Moran CP, English S, Beringer T, Lindsay JR. Real World Experience of Denosumab Treatment in the Belfast Osteoporosis Service. Ulster Med J 2019;88(3):150-6.
- Health Insurance Review & Aseessment Service. Notification 2020-221. Available from https://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA020002000100&brdScnBltNo=4&brdBltNo=8254. Accessed July 11, 2022
- Lyu H, Zhao SS, Yoshida K, et al. Delayed denosumab injections and bone mineral density response: An electronic health recordbased study. J Clin Endocrinol Metab 2020;105(5):1435-44. https://doi.org/10.1210/clinem/dgz321
- Wong-Pack M, Kalani A, Hordyk J, et al. The effects of noncompliance to Prolia (denosumab) on the changes in bone mineral density: A retrospective review. J Osteoporos 2016;2016:7903128.
- Tsvetov G, Amitai O, Shochat T, Shimon I, Akirov A, Diker-Cohen T. Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low? Osteoporos Int 2020;31(4):655-65. https://doi.org/10.1007/s00198-019-05261-7
- Body JJ, Bone HG, de Boer RH, et al. Hypocalcaemia in patients with metastatic bone disease treated with denosumab. Eur J Cancer 2015;51(13):1812-21. https://doi.org/10.1016/j.ejca.2015.05.016